StockData

Generate Biomedicines, Inc. (GENB) stock

GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)

Close on Nov 17, 2026Market cap $1.26BP/E –Yield –

Generate Biomedicines profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 2026-2077.2%−1559.6
Q2 FY2026Jun 30, 2026-1065.2%−592.4
Q1 FY2026Mar 31, 2026-850.6%–
Q3 FY2025Sep 30, 2025-556.5%–
Q2 FY2025Jun 30, 2025-517.6%–
Q1 FY2025Mar 31, 2025-472.7%–

More Generate Biomedicines figures

See a number that looks wrong?